Theranostic applications of phage display to control leishmaniasis: Selection of biomarkers for serodiagnostics, vaccination, and immunotherapy

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 48, Issue 4, 2015, Pages 370-379

  Coelho, Eduardo Antonio Ferraz ^a   Chávez Fumagalli, Miguel Angel ^a   Costa, Lourena Emanuele ^a   Tavares, Carlos Alberto Pereira ^a   Soto, Manuel ^b   Goulart, Luiz Ricardo ^c,d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b CSIC   (Spain)

^c FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mimotopes; Phage display; Serodiagnosis; Vaccine; Visceral leishmaniasis

Indexed keywords

IMMUNOGLOBULIN G; BIOLOGICAL MARKER;

BACTERIOPHAGE; COMMUNITY CARE; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LEISHMANIA; LEISHMANIASIS; NONHUMAN; PHAGE DISPLAY; PREVENTION AND CONTROL; REVIEW; SERODIAGNOSIS; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BIOTECHNOLOGY; CELL SURFACE DISPLAY; DRUG DEVELOPMENT; GENETIC PROCEDURES; IMMUNOLOGY; MOUSE; PROCEDURES;

BACTERIA (MICROORGANISMS);

ANIMALS; BIOMARKERS; BIOTECHNOLOGY; CELL SURFACE DISPLAY TECHNIQUES; DRUG DISCOVERY; GENETIC TECHNIQUES; HUMANS; IMMUNOTHERAPY; LEISHMANIASIS; MICE; MICE, INBRED BALB C; VACCINATION;

EID: 84940383336     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/0037-8682-0096-2015     Document Type: Review

References (82)

1. Ashford RW. The leishmaniases as emerging and reemerging zoonoses. Int J Parasitol 2000; 30:1269-1281.
2. Gramiccia M, Gradoni L. The current status of zoonotic leishmaniases and approaches to disease control. Int J Parasitol 2005; 35:1169-1180.
3. Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L. Canine leishmaniosis-new concepts and insights on an expanding zoonosis: part one. Trends Parasitol 2008; 24:324-330.
4. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PloS One 2012; 7:1-12.
5. Cruz I, Acosta L, Gutiérrez MN, Nieto J, Cañavate C, Deschutter J, et al. A canine leishmaniasis pilot survey in an emerging focus of visceral leishmaniasis: Posadas (Misiones, Argentina). BMC Infect Dis 2010; 10:342-345.
6. Duprey ZH, Steurer FJ, Rooney JA, Kirchhoff LV, Jackson JE, Rowton ED, et al. Canine visceral leishmaniasis, 2000-2003. Emerg Infect Dis 2006; 12:440-446.
7. Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hassan SM, et al. Do the diminishing effi cacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a fi rst-line drug? An observational study of 80 cases. Ann Trop Med Parasitol 1998; 92:561-569.
8. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-1107.
9. Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19:502-508.
10. World Health Organization (WHO). Control of the leishmaniases: report of a meeting of the 399 WHO Expert Committee on the Control of Leishmaniases. (Cited 2015 June). Available at: http:// whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf. 2010
11. Egger SS, Meier S, Leu C, Christen S, Gratwohl A, Krähenbühl S, et al. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant 2009; 45:1197-1203.
12. Tonelli RR, Colli W, Alves MJM. Selection of binding targets in parasites using phage-display and aptamer libraries in vivo and in vitro. Front Immunol 2012; 3:1-16.
13. Clark JR, March JB. Bacteriophage-mediated nucleic acid immunisation. FEMS Immunol Med Microbiol 2004; 40:21-26.
14. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228:1315-1317.
15. Rodi DJ, Makowski L. Phage display technology-fi nding a needle in a vast molecular haystack. Curr Opin Biotechnol 1999; 10:87-93.
16. Sidhu SS. Phage display in pharmaceutical biotechnology. Curr Opin Biotechnol 2000; 11:610-616.
17. Manoutcharian K, Gevorkian G, Cano A, Almagro JC. Phage displayed biomolecules as preventive and therapeutic agents. Curr Pharm Biotechnol 2001; 2:217-223.
18. Matthews LJ, Davis R, Smith GP. Immunogenicity fi t subunit vaccine components via epitope discovery from natural peptide libraries. J Immunol 2002; 169:837-846.
19. Hiemstra HS, Van Veelen PA, Schloot NC, Geluk A, Van Meijgaarden KE, Willemen SJ, et al. Defi nition of natural T cell antigens with mimicry epitopes obtained from dedicated synthetic peptide libraries. J Immunol 1998; 161:4078-4082.
20. Crameri R, Suter M. Display of biologically active proteins on the surface of fi lamentous phages: a cDNA cloning system for selection of functional gene products linked to the genetic information responsible for their production. Gene 1993; 137:69-75.
21. Bakhshinejad B, Sadeghizadeh M. Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection. World J Gastroenterol 2014; 20:11671-11683.
22. Greenwood J, Willis A, Perham R. Multiple display of foreign peptides on a fi lamentous bacteriophage. Peptides from Plasmodium falciparum circum-sporozoite protein as antigens. J Mol Biol 1991; 220:821-827.
23. Monette M, Opella S, Greenwood J, Willis A, Perham R. Structure of a malaria parasite antigenic determinant displayed on fi lamentous bacteriophage determined by NMR spectroscopy: implications for the structure of continuous peptide epitopes of proteins. Protein Sci 2001; 10:1150-1159.
24. Beghetto E, Spadoni A, Buffolano W, Pezzo M, Minenkova O, Pavoni E, et al. Molecular dissection of the human B-cell response against Toxoplasma gondii infection by lambda display of cDNA libraries. Int J Parasitol 2003; 33:163-173.
25. Cunha-Junior JP, Silva DA, Silva NM, Souza MA, Souza GR, Prudencio CR, et al. A4D12 monoclonal antibody recognizes a new linear epitope from SAG2A Toxoplasma gondii tachyzoites, identifi ed by phage display bioselection. Immunobiology 2010; 215:26-37.
26. Larralde OG, Martinez R, Camacho F, Amin N, Aguilar A, Talavera A, et al. Identifi cation of hepatitis A virus mimotopes by phage display, antigenicity and immunogenicity. J Virol Methods 2007; 140:49-58.
27. Manhani MN, Ribeiro VS, Cardoso R, Ueira-Vieira C, Goulart LR, Costa-Cruz JM. Specifi c phage-displayed peptides discriminate different forms of neurocysticercosis by antibody detection in the serum samples. Parasite Immunol 2011; 33:322-329.
28. Feliciano ND, Ribeiro VS, Santos FA, Fujimura PT, Gonzaga HT, Goulart LR, et al. Bacteriophage-fused peptides for serodiagnosis of human strongyloidiasis. PLoS Negl Trop Dis 2014; 8:e2792.
29. Reis CF, Carneiro AP, Vieira CU, Fujimura PT, Morari EC, Silva SJ, et al. An antibody-like peptide that recognizes malignancy among thyroid nodules. Cancer Lett 2013; 335:306-313.
30. Pitcovsky TA, Mucci J, Alvarez P, Leguizamon MS, Burrone O, Alzari PM, et al. Epitope mapping of trans-sialidase from Trypanosoma cruzi reveals the presence of several cross-reactive determinants. Infect Immunol 2001; 69:1869-1875.
31. Santos PS, Nascimento R, Rodrigues LP, Santos FA, Faria PC, Martins JR, et al. Functional epitope core motif of the Anaplasma marginale major surface protein 1a and its incorporation onto bioelectrodes for antibody detection. PLoS One 2012; 7:e33045.
32. Manoutcharian K, Díaz-Orea A, Gevorkian G, Fragoso G, Acero G, González E, et al. Recombinant bacteriophage-based multiepitope vaccine against Taenia solium pig cysticercosis. Vet Immunol Immunopathol 2004; 99:11-24.
33. Grabowska AM, Jennings IR, Laing P, Darsley M, Jameson CL, Swift L, et al. Immunisation with phage displaying peptides representing single epitopes of the glycoprotein g can give rise to partial protective immunity to HSV-2. Virology 2000; 269:47-53.
34. Hardy B, Raiter A. A mimotope peptide-based anti-cancer vaccine selected by BAT monoclonal antibody. Vaccine 2005; 23:4283-4291.
35. González E, Robles Y, Govezensky T, Bobes RJ, Gevorkian G, Manoutcharian K. Isolation of neurocysticercosis-related antigens from a genomic phage display library of Taenia solium. J Biomol Screen 2010; 15:1268-1273.
36. Tan GH, Yusoff K, Seow HF, Tan WS. Antigenicity and immunogenicity of the immunodominant region of hepatitis b surface antigen displayed on bacteriophage T7. J Med Virology 2005; 77:475-480.
37. Gu Y, Li J, Zhu X, Yang J, Li Q, Liu Z, et al. Trichinella spiralis: characterization of phage-displayed specifi c epitopes and their protective immunity in BALB/c mice. Exp Parasitol 2008; 118:66-74.
38. Frenkel D, Katz O, Solomon B. Immunization against Alzheimer's B-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci USA 2000; 97:11455-11459.
39. Santos PS, Sena AA, Nascimento R, Araújo TG, Mendes MM, Martins JR, et al. Epitope-based vaccines with the Anaplasma marginale MSP1a functional motif induce a balanced humoral and cellular immune response in mice. PLoS One 2013; 8:e60311.
40. Landon LA, Deutscher SL. Combinatorial discovery of tumor targeting peptides using phage display. J Cell Biochem 2003; 90:509-517.
41. Deutscher SL. Phage display in molecular imaging and diagnosis of cancer. Chem Rev 2010; 110:3196-3211.
42. Silva-Ribeiro V, Manhani MN, Cardoso R, Vieira CU, Goulart LR, Costa-Cruz JM. Selection of high affi nity peptide ligands for detection of circulating antibodies in neurocysticercosis. Immunol Lett 2010; 129:94-99.
43. Suo S, Wang X, Zarlenga D, Bu RE, Ren Y, Ren X. Phage display for identifying peptides that bind the spike protein of transmissible gastroenteritis virus and possess diagnostic potential. Virus Genes 2015; May 27 (Epub ahead of print).
44. Alban SM, Moura JF, Thomaz-Soccol V, Bührer-Sékula S, Alvarenga LM, Mira MT, et al. Phage display and synthetic peptides as promising biotechnological tools for the serological diagnosis of leprosy. PLoS One 2014; 9:e106222.
45. Trigo G, Martins TG, Fraga AG, Longatto-Filho A, Castro AG, Azeredo J, et al. Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model. PLoS Negl Trop Dis 2013; 7:e2183.
46. Manoutcharian K, Terrazas LI, Gevorkian G, Acero G, Petrossian P, Rodrigues M, et al. Phage-displayed T-cell epitope grafted into immunoglobulin heavy-chain complementarity-determining regions: an effective vaccine design tested in murine cysticercosis. Infect Immun 1999; 67:4764-4770.
47. Gaubin M, Fanutti C, Mishal Z, Durrbach A, de Berardinis P, Sartorius R, et al. Processing of fi lamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments. DNA Cell Biol 2003; 22:11-18.
48. Adhya S, Merril CR, Biswas B. Therapeutic and prophylactic applications of bacteriophage components in modern medicine. Cold Spring Harb Perspect Med 2014; 4:a012518.
49. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, et al. Targeting toll-like receptor 9 with CPG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy targeting toll-like receptor 9 with CPG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005; 11:361-369.
50. Hashiguchi S, Yamaguchi Y, Takeuchi O, Akira S, Sugimura K. Immunological basis of M13 phage vaccine: regulation under MyD88 and TLR9 signaling. Biochem Biophys Res Commun 2010; 402:19-22.
51. Gao W, He W, Zhao K, Lu H, Ren W, Du C, et al. Identifi cation of NCAM that interacts with the PHE-CoV spike protein. Virol J 2010; 7:254.
52. Zampoli M, Giantomassi J, Baldini S, Langoni H. Leishmania spp. and/or Trypanosoma cruzi diagnosis in dogs from endemic and nonendemic areas for canine visceral leishmaniasis. Vet Parasitol 2009; 164:118-123.
53. Silva DA, Madeira MF, Teixeira AC, Souza CM, Figueiredo FB. Laboratory tests performed on Leishmania seroreactive dogs euthanized by the leishmaniasis control program. Vet Parasitol 2011; 179:257-261.
54. Viol MA, Lima VMF, Aquino MCC, Gallo IG, Gallo IP, Alves D, et al. Detection of cross infections by Leishmania spp and Trypanosoma spp. in dogs using indirect immunoenzyme assay, indirect fl uorescent antibody test and polymerase chain reaction. Parasitol Res 2012; 111:1607-1613.
55. Machado RZ. A study of cross-reactivity in serum samples from dogs positive for Leishmania spp., Babesia canis and Ehrlichia canis in enzyme-linked immunosorbent assay and indirect fl uorescent antibody test. Rev Bras Parasitol 2008; 11:7-11.
56. Strauss-Ayali D, Jaffe CL, Burshtain O, Gonen L, Baneth G. Polymerase chain reaction using noninvasively obtained samples, for the detection of Leishmania infantum DNA in dogs. J Infect Dis 2004; 189:1729-1733.
57. Mettler M, Grimm F, Capelli G, Camp H, Deplazes D. Evaluation of enzyme-linked immunosorbent assays, an immunofl uorescentantibody test, and two rapid tests (immunochromatographicdipstick and gel tests) for serological diagnosis of symptomatic and asymptomatic Leishmania infections in dogs. J Clin Microbiol 2005; 43:5515-5519.
58. Courtenay O, Quinnell RJ, Garcez LM, Shaw JJ, Dye C. Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 2002; 186:1314-1320.
59. Reis AB, Teixeira-Carvalho A, Vale AM, Marques MJ, Giunchetti RC, Mayrink W, et al. Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Vet Immunol Immunopathol 2006; 112:102-116.
60. Coelho EAF, Ramírez L, Costa MAF, Coelho VTS, Martins VT, Chávez-Fumagalli MA, et al. Specifi c serodiagnosis of canine visceral leishmaniasis using Leishmania species ribosomal protein extracts. Clin Vaccine Immunol 2009; 16:1774-1780.
61. Costa LE, Lima MIS, Chávez-Fumagalli MA, Menezes-Souza D, Martins VT, Duarte MC, et al. Subtractive phage display selection from canine visceral leishmaniasis identifi es novel epitopes that mimic Leishmania infantum antigens with potential serodiagnosis applications. Clin Vaccine Immunol 2014; 21:96-106.
62. Fernandes AP, Costa MMS, Coelho EAF, Michalick MSM, Freitas E, Melo, MN, et al. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 2008; 26:5888-5895.
63. Chávez-Fumagalli MA, Martins VT, Testasicca MC, Lage DP, Costa LE, Lage PS, et al. Sensitive and specifi c serodiagnosis of Leishmania infantum infection in dogs by using peptides selected from hypothetical proteins identifi ed by an immunoproteomic approach. Clin Vaccine Immunol 2013; 20:835-841.
64. Modabber F. Leishmaniasis vaccines: past, present and future. Int J Antimicrob Agents 2010; 36S:58-61.
65. Das A, Ali N. Vaccine prospects of killed but metabolically active Leishmania against visceral leishmaniasis. Expert Rev Vaccines 2012; 11:783-785.
66. Ramírez L, Santos DM, Souza AP, Coelho EA, Barral A, Alonso, C, et al. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis. Vaccine 2013; 31:1312-1319.
67. Costa LE, Goulart LR, Pereira NCJ, Ingrid M, Lima S, Duarte MC, et al. Mimotope-based vaccines of Leishmania infantum antigens and their protective effi cacy against visceral leishmaniasis. Plos One 2014; 9:e110014.
68. Ramirez L, Villen LC, Duarte MC, Chávez-Fumagalli MA, Valadares DG, Santos DM, et al. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis. Parasit Vectors 2014; 2:3-10.
69. Martins VT, Chávez-Fumagalli MA, Costa LE, Canavaci AMC, Martins AMCC, Lage PS, et al. Antigenicity and protective effi cacy of a Leishmania amastigote-specifi c protein, member of the super-oxygenase family, against visceral leishmaniasis. PLoS Negl Trop Dis 2013; 7:e2148.
70. Dey R, Dagur PK, Selvapandiyan A, McCoy JP, Salotra P, Duncan R, et al. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice. J Immunol 2013; 190:2138-2149.
71. Rosa R, Marques C, Rodrigues OR, Santos-Gomes GM. Immunization with Leishmania infantum released proteins confers partial protection against parasite infection with a predominant Th1 specifi c immune response. Vaccine 2007; 25:4525-4532.
72. Iborra S, Parody N, Abánades DR, Bonay P, Prates D, Novais FO, et al. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect 2008; 10:1133-1141.
73. Coelho EAF, Tavares CA, Carvalho FA, Chaves KF, Teixeira KN, Rodrigues RC, et al. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 2003; 71:3988-3994.
74. Goto Y, Bhatia A, Raman VS, Liang H, Mohamath R, Picone AF, et al. KSAC, the fi rst defi ned polyprotein vaccine candidate for visceral leishmaniasis. Clin Vaccine Immunol 2011; 18:1118-1124.
75. Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Costa MMS, Resende SA, et al. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. Microbes Infect 2007; 9:1070-1077.
76. Carrión J, Folgueira C, Alonso C. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells. Vaccine 2008; 26:2537-2544.
77. Spitzer N, Jardim A, Lippert D, Olafson RW. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine 1999; 17:1298-1300.
78. Basu R, Roy S, Walden P. HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J Infect Dis 2007; 195:1373-1380.
79. Barral A, Pedral-Sampaio D, Grimaldi Jr G, Momen H, McMahon-Pratt D, Ribeiro-de-Jesus A, et al. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg 1991; 44:536-546.
80. Gomes R, Teixeira C, Teixeira MJ, Oliveira F, Menezes MJ, Silva C, et al. Immunity to a salivary protein of a sand fl y vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci USA 2008; 105:7845-7850.
81. Carrión J, Nieto A, Iborra S, Iniesta V, Soto M, Folgueira C, et al. Immunohistological features of visceral leishmaniasis in BALB/c mice. Parasite Immunol 2006; 28:173-183.
82. Oliveira DM, Valadares DG, Duarte MC, Costa LE, Martins VT, Gomes RF, et al. Evaluation of parasitological and immunological parameters of Leishmania chagasi infection in BALB/c mice using different doses and routes of inoculation of parasites. Parasitol Res 2012; 110:1277-1285.